Agilent Technologies, Inc. · NYSE:A
Agilent Technologies — Q2 2021 Earnings Presentation
8 slides from Agilent Technologies's earnings presentation, May 25, 2021
Slide 1: Agilent Technologies Q2'21 Results Presentation
Agilent Technologies Q2’21 Results Presentation
Slide 2: Safe Harbor
Safe Harbor These presentations contain forward-looking statements (including, without limitation, information, and future guidance on the company’s goals, priorities, revenue, revenue growth, earnings per share, operating margin, operating cash flow, capital expenditures, capital allocation, growth
Slide 3: Agilent Results Q2'21
Agilent Results Q2'21 Scale and leading technology across Analytical Laboratories and Clinical & Dx markets Q2'21 Financial Metrics Q2’21 Highlights • Revenues: $1.52B, +19.3% y/y • Growth: Strong results across all end markets and regions core(1)(2),+23.2% reported (+3.9% FX). highlighted by contin
Slide 4: Life Sciences & Applied Markets Group (LSAG)
Life Sciences & Applied Markets Group (LSAG) • Q2 core revenue performance reflected broad Instrumentation and Informatics based strength across all end markets led by Pharma. for Analytical Laboratories Momentum across all platforms led by LC, Mass Spec, and Cell Analysis. • Announced the InfinityL
Slide 5: Agilent Cross Lab Group (ACG)
Agilent Cross Lab Group (ACG) Analytical Laboratory • Mid-teens revenue growth in Q2 was broad- Consumables and Services based and well balanced between services and consumables. Excellent execution of the cross-lab strategy and strength in China continue to drive results. • ACG introduced “One-Stop
Slide 6: Diagnostics and Genomics Group (DGG)
Diagnostics and Genomics Group (DGG) • Q2 core revenue growth was broad-based Pathology, Genomics, and Nucleic Acid Manufacturing across the entire portfolio and led by continued strength in NASD, continued demand for genomics instrumentation and consumables, and emerging recovery in cancer diagnost
Slide 7: Growth in a $58B Market – Q2'21 Results by End Market
Growth in a $58B Market – Q2'21 Results by End Market Continued momentum in Pharma and Food; Emerging recovery in Dx, A&G, and C&E Analytical Laboratory End Markets ▪ Q2'21 revenues: +21% y/y on core(2) basis ▪ Pharma & Biotech: Up 29% with strong double-digit growth across all geographies and busin
Slide 8: Q3'21 and FY21 Guidance
Q3’21 and FY21 Guidance and Forward-looking Considerations Based on April 30, 2021 Exchange Rates Q3’21 Guidance (1) FY21 Guidance (1) Low End High End Low End High End Net Revenue ($M) $1,510 $1,540 Net Revenue ($M) $6,150 $6,210 Y/Y Core Revenue Growth (2) 15% 17.5% Y/Y Core Revenue Growth (2) 12%